Financial News

Intercept Downgraded To Sell From Neutral At H.C. Wainwright

H.C. Wainwright analyst Ed Arce downgraded Intercept Pharmaceuticals to Sell from Neutral with a price target of $25, down from $46, after the company disclosed that its Chief Medical Officer Jason Campagna has decided to resign effective March 5.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback